EPS: As of FY2025 Q1, the actual value is USD -0.35.<h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of - $23.3 million for the three months ended March 31, 2025, compared to - $54.4 million for the same period in 2024, representing a decrease of 57%.</li><li>Operating Expenses: Total operating expenses increased by 45% to $32.2 million for the three months ended March 31, 2025, from $22.2 million for the same period in 2024.</li><li>Research and Development Expenses: Increased by 100% to $23.4 million for the three months ended March 31, 2025, from $11.7 million for the same period in 2024.</li><li>General and Administrative Expenses: Decreased by 16% to $8.8 million for the three months ended March 31, 2025, from $10.5 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $29.4 million for the three months ended March 31, 2025, compared to - $16.6 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $162.5 million for the three months ended March 31, 2025, with no comparable activity in 2024.</li><li>Net Cash Provided by Financing Activities: $1.0 million for the three months ended March 31, 2025, compared to $169.2 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of 2022 USD Financing Warrants: The company reported a change in fair value of $7.0 million for the three months ended March 31, 2025, compared to - $32.9 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Mind Medicine (MindMed) Inc. plans to continue the clinical development of its lead product candidates MM120 and MM402, with ongoing Phase 3 trials for MM120 in generalized anxiety disorder and major depressive disorder, and further trials for MM402 in autism spectrum disorder.</li><li>Non-Core Business: The company is exploring additional programs through external collaborations to expand its drug development pipeline and broaden the potential applications of its lead product candidates.</li><li>Priority: The company expects its cash runway to extend at least 12 months beyond the first Phase 3 topline data readout for MM120 in GAD, indicating a strategic focus on advancing clinical trials and achieving regulatory milestones.</li></ul>

Mind Medicine MindMed | 10-Q: FY2025 Q1 EPS: USD -0.35